title: Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases.
abstract: The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented-38 % under treatment with biologicals-of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases.
authors.affiliation: Epidemiology Unit, German Rheumatism Research Centre Berlin, Leibniz Institute, Charitéplatz 1, 10117, Berlin, Germany, sengler@drfz.de.
authors.forename: C
authors.initials: C
authors.lastname: Sengler
authors.forename: M
authors.initials: M
authors.lastname: Niewerth
authors.forename: T
authors.initials: T
authors.lastname: Kallinich
authors.forename: A
authors.initials: A
authors.lastname: Nimtz-Talaska
authors.forename: M
authors.initials: M
authors.lastname: Haller
authors.forename: H-I
authors.initials: HI
authors.lastname: Huppertz
authors.forename: K
authors.initials: K
authors.lastname: Minden
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000293:Adolescent; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000150:complications / Q000188:drug therapy; D001323:Autoantibodies / Q000737:chemistry; D002648:Child; D002675:Child, Preschool; D016208:Databases, Factual; D005260:Female; D005858:Germany; D006304:Health Status; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D012216:Rheumatic Diseases / Q000150:complications* / Q000276:immunology*; D012219:Rheumatology / Q000592:standards; D011795:Surveys and Questionnaires; D014611:Vaccination
chemical_list: D000276:Adjuvants, Immunologic; D018501:Antirheumatic Agents; D001323:Autoantibodies; D007252:Influenza Vaccines; D008727:Methotrexate